Cargando…

Whole genome sequencing in oncology: using scenario drafting to explore future developments

BACKGROUND: In oncology, Whole Genome Sequencing (WGS) is not yet widely implemented due to uncertainties such as the required infrastructure and expertise, costs and reimbursements, and unknown pan-cancer clinical utility. Therefore, this study aimed to investigate possible future developments faci...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Ven, Michiel, Simons, Martijn J. H. G., Koffijberg, Hendrik, Joore, Manuela A., IJzerman, Maarten J., Retèl, Valesca P., van Harten, Wim H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088550/ https://www.ncbi.nlm.nih.gov/pubmed/33933021 http://dx.doi.org/10.1186/s12885-021-08214-8

Ejemplares similares

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer
por: van de Ven, Michiel, et al.
Publicado: (2022)

Scenario drafting to anticipate future developments in technology assessment
por: Retèl, Valesca P, et al.
Publicado: (2012)

The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
por: van Delft, Frederik, et al.
Publicado: (2020)

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology
por: Joosten, S.E.P., et al.
Publicado: (2016)

Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy
por: van Delft, Frederik, et al.
Publicado: (2021)

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
por: Simons, Martijn J. H. G., et al.
Publicado: (2021)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

Early budget impact analysis on magnetic seed localization for non-palpable breast cancer surgery
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments
por: van Harten, Wim, et al.
Publicado: (2017)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2022)

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
por: van Amerongen, Rosa A, et al.
Publicado: (2016)

Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes
por: Lindenberg, Melanie A., et al.
Publicado: (2022)

Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

Association between genomic recurrence risk and well-being among breast cancer patients
por: Retèl, Valesca P, et al.
Publicado: (2013)

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product
por: Lindenberg, Melanie A., et al.
Publicado: (2018)

Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations
por: Behr, Carina M., et al.
Publicado: (2023)

Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo- or bioradiotherapy
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models
por: Degeling, Koen, et al.
Publicado: (2017)

Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
por: IJzerman, Maarten J., et al.
Publicado: (2017)

Point‐of‐care testing in primary care: A systematic review on implementation aspects addressed in test evaluations
por: Lingervelder, Deon, et al.
Publicado: (2019)

Health Economic Evidence of Point-of-Care Testing: A Systematic Review
por: Lingervelder, Deon, et al.
Publicado: (2021)

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
por: Mfumbilwa, Zakile A., et al.
Publicado: (2023)

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy
por: Retèl, Valesca P, et al.
Publicado: (2011)

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room
por: Patel, Sejal, et al.
Publicado: (2020)

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation
por: Verbeek, Joost G. E., et al.
Publicado: (2023)

Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process
por: Degeling, Koen, et al.
Publicado: (2020)

Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer
por: Degeling, Koen, et al.
Publicado: (2018)

Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation
por: Behr, Carina M., et al.
Publicado: (2022)

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
por: Retèl, Valesca P., et al.
Publicado: (2018)

The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care
por: Kip, Michelle M. A., et al.
Publicado: (2017)

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation
por: van Harten, WH, et al.
Publicado: (2016)

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms
por: Verbeek, Joost G. E., et al.
Publicado: (2019)

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
por: Byng, Danalyn, et al.
Publicado: (2021)

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019)

Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer
por: van Delft, Frederik A., et al.
Publicado: (2022)

Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility
por: Berghuis, A. M. Sofie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2t513e82foh0fe7339equfh1tv